{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:51Z","timestamp":1790207751819,"version":"4.1.0"},"reference-count":106,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Selective internal radiotherapy (SIRT) has emerged as a viable treatment for both primary and secondary liver neoplasms, exhibiting favorable efficacy and low toxicity in clinical applications. This review synthesizes key studies that investigate the safety and efficacy of SIRT, particularly in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, along with its application in treating liver metastatic malignancies. SIRT demonstrates superior time to progression, enhanced quality of life, and reduced toxicity compared with conventional therapies, including tyrosine kinase inhibitors and transarterial chemoembolization, despite comparable overall survival benefits. Notwithstanding these gains, additional study is warranted to enhance combination therapy, improving dosimetry models. Further investigation is also needed to explore the use of SIRT in extrahepatic cancers. Personalized dosimetry holds significant potential for improving patient outcomes and warrants further exploration in several key areas, including biodistribution simulation, dosimetry calculation method refinement, intraprocedural visualization advancement, and posttreatment dosimetry evaluation technique improvement. Furthermore, the integration of SIRT with systemic therapies has demonstrated potential for synergistic effects, thereby enhancing tumor response and survival outcomes. SIRT is a significant enhancement to the treatment repertoire for liver neoplasms, with ongoing research further broadening its clinical applicability and improving patient outcomes.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_707_25","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:00:35Z","timestamp":1779951635000},"page":"222-230","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Advancements in selective internal radiotherapy: Efficacy, safety, and future directions"],"prefix":"10.4103","volume":"22","author":[{"given":"Linhong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20260528","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/jcrt.jcrt_1954_24","article-title":"Impact of materia medica in combination with transarterial chemoembolization on inflammatory markers in patients with hepatocellular carcinoma: A systematic review and meta-analysis","volume":"21","author":"Yu","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00259-011-1812-2","article-title":"EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds","volume":"38","author":"Giammarile","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","article-title":"EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds","volume":"49","author":"Weber","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11605-022-05559-8","article-title":"Yttrium-90 radioembolization: Current indications and outcomes","volume":"27","author":"Hamad","year":"2023","journal-title":"J Gastrointest Surg"},{"key":"R6-20260528","first-page":"621","article-title":"Availability of yttrium-90 from strontium-90: A nuclear medicine perspective","volume":"27","author":"Chakravarty","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/s-0040-1720954","article-title":"Yttrium-90 radioembolization dosimetry: What trainees need to know","volume":"37","author":"Villalobos","year":"2020","journal-title":"Semin Intervent Radiol"},{"key":"R8-20260528","article-title":"TheraSphere yttrium-90 microspheres package insert","author":"Nordion","year":"2004","journal-title":"MDS Nordion, Kanata, Canada"},{"key":"R9-20260528","author":"SIRTEX","year":"2004","journal-title":"SIR-Spheres\u00aeYttrium-90 Microspheres (Package Insert)"},{"key":"R10-20260528","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.ijrobp.2004.09.004","article-title":"Pathologic response and microdosimetry of (90) Y microspheres in man: Review of four explanted whole livers","volume":"60","author":"Kennedy","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R11-20260528","first-page":"107","article-title":"Advances in radioembolization \u2013Embolics and isotopes","volume":"2","author":"Burrill","year":"2011","journal-title":"J Nucl Med Radiat Ther"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.116.184713","article-title":"Resin versus glass microspheres for (90) Y transarterial radioembolization: Comparing survival in unresectable hepatocellular carcinoma using pretreatment partition model dosimetry","volume":"58","author":"Van Der Gucht","year":"2017","journal-title":"J Nucl Med"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/hpb.12135","article-title":"Early arterial stasis during resin-based yttrium-90 radioembolization: Incidence and preliminary outcomes","volume":"16","author":"Piana","year":"2014","journal-title":"HPB (Oxford)"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.adro.2016.08.003","article-title":"The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres","volume":"1","author":"Westcott","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"R15-20260528","first-page":"110662","article-title":"A new radioactive microsphere: Y-90 carbon microsphere for selective internal radiation therapy of advanced liver cancer","author":"Zhao","year":"2024","journal-title":"Chin Chem Lett"},{"key":"R16-20260528","first-page":"70","article-title":"Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin","volume":"35","author":"Leung","year":"1994","journal-title":"J Nucl Med"},{"key":"R17-20260528","first-page":"1209","article-title":"Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations","volume":"47","author":"Gulec","year":"2006","journal-title":"J Nucl Med"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jvir.2015.07.021","article-title":"Intrahepatic activity distribution in radioembolization with yttrium-90-labeled resin microspheres using the body surface area method \u2013A less than perfect model","volume":"26","author":"Grosser","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00330-020-07231-8","article-title":"Yttrium-90 radioembolization using MIRD dosimetry with resin microspheres","volume":"31","author":"Sarwar","year":"2021","journal-title":"Eur Radiol"},{"key":"R20-20260528","first-page":"293","article-title":"Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer","volume":"24","author":"Ho","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40658-020-00343-6","article-title":"Impact of the dosimetry approach on the resulting (90) Y radioembolization planned absorbed doses based on (99m) Tc-MAA SPECT-CT: Is there agreement between dosimetry methods?","volume":"7","author":"Mor\u00e1n","year":"2020","journal-title":"EJNMMI Phys"},{"key":"R22-20260528","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s00259-015-3059-9","article-title":"A multicentre comparison of quantitative (90) Y PET\/CT for dosimetric purposes after radioembolization with resin microspheres: The QUEST Phantom Study","volume":"42","author":"Willowson","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"e0246848","DOI":"10.1371\/journal.pone.0246848","article-title":"Evaluation of qualitative and quantitative data of Y-90 imaging in SPECT\/CT and PET\/CT phantom studies","volume":"16","author":"Kubik","year":"2021","journal-title":"PLoS One"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"100633","DOI":"10.1016\/j.jhepr.2022.100633","article-title":"Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study","volume":"5","author":"Kolligs","year":"2023","journal-title":"JHEP Rep"},{"key":"R25-20260528","first-page":"1637","article-title":"Hepatic radioembolization with yttrium-90 containing glass microspheres: Preliminary results and clinical follow-up","volume":"35","author":"Andrews","year":"1994","journal-title":"J Nucl Med"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/cncr.29275","article-title":"Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis","volume":"121","author":"Kokabi","year":"2015","journal-title":"Cancer"},{"key":"R27-20260528","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","article-title":"Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study","volume":"57","author":"Mazzaferro","year":"2013","journal-title":"Hepatology"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation segmentectomy: Potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"R30-20260528","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): A single-centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R31-20260528","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: The LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"R32-20260528","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jvir.2024.10.021","article-title":"Resin-based yttrium-90 radioembolization as a bridging or downstaging treatment to liver transplantation for hepatocellular carcinoma","volume":"36","author":"Bonne","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"R33-20260528","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.hpb.2019.03.360","article-title":"Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma","volume":"21","author":"Labgaa","year":"2019","journal-title":"HPB (Oxford)"},{"key":"R34-20260528","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2967\/jnumed.123.266211","article-title":"Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: Updated analysis of DOSISPHERE-01 Trial","volume":"65","author":"Garin","year":"2024","journal-title":"J Nucl Med"},{"key":"R35-20260528","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jvir.2017.08.026","article-title":"Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma","volume":"29","author":"Biederman","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"R36-20260528","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jvir.2014.03.030","article-title":"Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity","volume":"25","author":"Padia","year":"2014","journal-title":"J Vasc Interv Radiol"},{"key":"R37-20260528","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R38-20260528","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"R39-20260528","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"R40-20260528","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00259-015-3210-7","article-title":"Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis","volume":"43","author":"Edeline","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R41-20260528","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/liv.13098","article-title":"A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib","volume":"36","author":"de la Torre","year":"2016","journal-title":"Liver Int"},{"key":"R42-20260528","doi-asserted-by":"crossref","first-page":"e90909","DOI":"10.1371\/journal.pone.0090909","article-title":"Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma","volume":"9","author":"Chow","year":"2014","journal-title":"PLoS One"},{"key":"R43-20260528","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2147\/JHC.S318865","article-title":"A prospective phase II study of safety and efficacy of sorafenib followed by (90) Y glass microspheres for patients with advanced or metastatic hepatocellular carcinoma","volume":"8","author":"Kaseb","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"R44-20260528","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/liv.12622","article-title":"Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: Analysis of the European multicentre trial SORAMIC","volume":"35","author":"Ricke","year":"2015","journal-title":"Liver Int"},{"key":"R45-20260528","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"R46-20260528","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.12750","article-title":"Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"Kolligs","year":"2015","journal-title":"Liver Int"},{"key":"R47-20260528","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/pon.725","article-title":"Quality of life in patients diagnosed with primary hepatocellular carcinoma: Hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere)","volume":"13","author":"Steel","year":"2004","journal-title":"Psychooncology"},{"key":"R48-20260528","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"R49-20260528","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","article-title":"Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma","volume":"36","author":"Moreno-Luna","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R50-20260528","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","article-title":"Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma","volume":"140","author":"Salem","year":"2011","journal-title":"Gastroenterology"},{"key":"R51-20260528","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A comparative analysis of transarterial downstaging for hepatocellular carcinoma: Chemoembolization versus radioembolization","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"key":"R52-20260528","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/cncr.24884","article-title":"Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: A two-cohort study","volume":"116","author":"Carr","year":"2010","journal-title":"Cancer"},{"key":"R53-20260528","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00270-017-1826-7","article-title":"Safety and efficacy of transarterial radioembolization combined with chemoembolization for bilobar hepatocellular carcinoma: A single-center retrospective study","volume":"41","author":"Kwon","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R54-20260528","doi-asserted-by":"crossref","first-page":"e005457","DOI":"10.1136\/jitc-2022-005457","article-title":"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: A phase 2, single-arm study","volume":"10","author":"de la Torre-Al\u00e1ez","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R55-20260528","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): A single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R56-20260528","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","article-title":"A phase I\/IIa trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R57-20260528","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","article-title":"A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis Hepatocellular carcinoma","volume":"29","author":"Yu","year":"2024","journal-title":"Oncologist"},{"key":"R58-20260528","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.18632\/oncotarget.28060","article-title":"Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma","volume":"12","author":"Paz-Fumagalli","year":"2021","journal-title":"Oncotarget"},{"key":"R59-20260528","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00259-018-4199-5","article-title":"Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: A large single-center experience","volume":"46","author":"Bourien","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R60-20260528","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/bjc.2016.191","article-title":"Yttrium-90 radioembolization for unresectable\/recurrent intrahepatic cholangiocarcinoma: A survival, efficacy and safety study","volume":"115","author":"Mosconi","year":"2016","journal-title":"Br J Cancer"},{"key":"R61-20260528","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","article-title":"Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option","volume":"17","author":"Saxena","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R62-20260528","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1023\/A:1013569329846","article-title":"Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer","volume":"12","author":"Gray","year":"2001","journal-title":"Ann Oncol"},{"key":"R63-20260528","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J Clin Oncol"},{"key":"R64-20260528","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","article-title":"Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy","volume":"28","author":"Hendlisz","year":"2010","journal-title":"J Clin Oncol"},{"key":"R65-20260528","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"key":"R66-20260528","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.220387","article-title":"Survival and toxicities after (90) Y transarterial radioembolization of metastatic colorectal cancer in the RESIN registry","volume":"305","author":"Emmons","year":"2022","journal-title":"Radiology"},{"key":"R67-20260528","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.bjc.6605770","article-title":"Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases","volume":"103","author":"Cosimelli","year":"2010","journal-title":"Br J Cancer"},{"key":"R68-20260528","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"key":"R69-20260528","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.115.165050","article-title":"Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: A large single-center experience in 81 patients","volume":"57","author":"Fendler","year":"2016","journal-title":"J Nucl Med"},{"key":"R70-20260528","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2967\/jnumed.115.165613","article-title":"Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer","volume":"57","author":"Michl","year":"2016","journal-title":"J Nucl Med"},{"key":"R71-20260528","first-page":"679","article-title":"(90) Y Radioembolization in the treatment of neuroendocrine neoplasms: Results of an international multicenter retrospective study","volume":"63","author":"Schaarschmidt","year":"2022","journal-title":"J Nucl Med"},{"key":"R72-20260528","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00270-021-02925-y","article-title":"Role of radioembolization in the management of liver-dominant metastatic renal cell carcinoma: A single-center, retrospective study","volume":"44","author":"Bibok","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R73-20260528","doi-asserted-by":"crossref","first-page":"bvac091","DOI":"10.1210\/jendso\/bvac091","article-title":"Yttrium-90 selective internal radiation therapy plus cryoablation for recurrent adrenocortical carcinoma with liver metastases","volume":"6","author":"Lin","year":"2022","journal-title":"J Endocr Soc"},{"key":"R74-20260528","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13550-021-00755-0","article-title":"Yttrium-90 radioembolization of isolated hepatic adrenocortical carcinoma metastases with negative surgical pathology","volume":"11","author":"Lu","year":"2021","journal-title":"EJNMMI Res"},{"key":"R75-20260528","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5306\/wjco.v9.i1.20","article-title":"Yttrium-90 microsphere selective internal radiation therapy for liver metastases following systemic chemotherapy and surgical resection for metastatic adrenocortical carcinoma","volume":"9","author":"Makary","year":"2018","journal-title":"World J Clin Oncol"},{"key":"R76-20260528","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00259-013-2383-1","article-title":"Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study","volume":"40","author":"Botta","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R77-20260528","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jvir.2016.04.001","article-title":"Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: Results in 630 patients","volume":"27","author":"Pisco","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"R78-20260528","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jvir.2021.01.282","article-title":"Yttrium-90 radioembolization to the prostate gland: Proof of concept in a canine model and clinical translation","volume":"32","author":"Mouli","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"R79-20260528","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13550-020-00679-1","article-title":"Yttrium-90 radioembolization as a possible new treatment for brain cancer: Proof of concept and safety analysis in a canine model","volume":"10","author":"Pasciak","year":"2020","journal-title":"EJNMMI Res"},{"key":"R80-20260528","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jvir.2012.10.027","article-title":"Radioembolization of renal cell carcinoma using yttrium-90 microspheres","volume":"24","author":"Hamoui","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"R81-20260528","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clgc.2022.05.006","article-title":"RESIRT: A phase 1 study of selective internal radiation therapy using Yttrium-90 resin microspheres in patients with primary renal cell carcinoma","volume":"20","author":"de Souza","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"R82-20260528","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s00270-013-0690-3","article-title":"Y90-radioembolization of lung metastases via the bronchial artery: A report of 2 cases","volume":"36","author":"Ricke","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R83-20260528","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1002\/mp.15303","article-title":"Automated segmentation of lung, liver, and liver tumors from Tc-99m MAA SPECT\/CT images for Y-90 radioembolization using convolutional neural networks","volume":"48","author":"Chaichana","year":"2021","journal-title":"Med Phys"},{"key":"R84-20260528","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1002\/mp.15270","article-title":"A deep-learning-based prediction model for the biodistribution of (90) Y microspheres in liver radioembolization","volume":"48","author":"Plachouris","year":"2021","journal-title":"Med Phys"},{"key":"R85-20260528","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2967\/jnumed.115.169987","article-title":"Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-microspheres used in preradioembolization dosimetry: Influence on the liver-lung shunt","volume":"57","author":"Grosser","year":"2016","journal-title":"J Nucl Med"},{"key":"R86-20260528","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s00259-015-3048-z","article-title":"Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types","volume":"42","author":"Lam","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R87-20260528","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/IJN.S187153","article-title":"(99m) Tc-radiolabeled composites enabling in vivo imaging of arterial dispersal and retention of microspheres in the vascular network of rabbit lungs, liver, and liver tumors","volume":"14","author":"Stephens","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"R88-20260528","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jvir.2022.08.027","article-title":"Accuracy and safety of scout dose resin Yttrium-90 microspheres for radioembolization therapy treatment planning: A prospective single-arm clinical trial","volume":"33","author":"Kokabi","year":"2022","journal-title":"J Vasc Interv Radiol"},{"key":"R89-20260528","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00259-019-04460-y","article-title":"The superior predictive value of (166) Ho-scout compared with (99m) Tc-macroaggregated albumin prior to (166) Ho-microspheres radioembolization in patients with liver metastases","volume":"47","author":"Smits","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R90-20260528","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.ijrobp.2016.07.021","article-title":"Selective internal radiation therapy with Yttrium-90 glass microspheres: Biases and uncertainties in absorbed dose calculations between clinical dosimetry models","volume":"96","author":"Mikell","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R91-20260528","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40658-015-0119-y","article-title":"Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for (90) Y microsphere selective internal radiation therapy","volume":"2","author":"Mikell","year":"2015","journal-title":"EJNMMI Phys"},{"key":"R92-20260528","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1007\/s00259-023-06567-9","article-title":"MIDOS: A novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors","volume":"51","author":"Huesa-Berral","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R93-20260528","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1007\/s00259-022-05902-w","article-title":"Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): A phase I trial towards adaptive, image-controlled treatment delivery","volume":"49","author":"Roosen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R94-20260528","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00270-014-1042-7","article-title":"Radioembolization dosimetry: The road ahead","volume":"38","author":"Smits","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R95-20260528","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1088\/0031-9155\/60\/4\/1667","article-title":"A PET detector prototype based on digital SiPMs and GAGG scintillators","volume":"60","author":"Schneider","year":"2015","journal-title":"Phys Med Biol"},{"key":"R96-20260528","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13550-019-0512-y","article-title":"Optimising quantitative (90) Y PET imaging: An investigation into the effects of scan length and Bayesian penalised likelihood reconstruction","volume":"9","author":"Scott","year":"2019","journal-title":"EJNMMI Res"},{"key":"R97-20260528","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-021-05188-4","article-title":"High quality imaging and dosimetry for yttrium-90 ((90) Y) liver radioembolization using a SiPM-based PET\/CT scanner","volume":"48","author":"Duan","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R98-20260528","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/mp.12717","article-title":"Absorbed dose kernel and self-shielding calculations for a novel radiopaque glass microsphere for transarterial radioembolization","volume":"45","author":"Church","year":"2018","journal-title":"Med Phys"},{"key":"R99-20260528","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s00259-009-1210-1","article-title":"Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT","volume":"36","author":"Lhommel","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R100-20260528","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1148\/radiol.13121038","article-title":"PET\/MR imaging: Technical aspects and potential clinical applications","volume":"267","author":"Torigian","year":"2013","journal-title":"Radiology"},{"key":"R101-20260528","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40658-018-0222-y","article-title":"Comparison of PET\/CT and PET\/MR imaging and dosimetry of yttrium-90 ((90) Y) in patients with unresectable hepatic tumors who have received intra-arterial radioembolization therapy with (90) Y microspheres","volume":"5","author":"Kne\u0161aurek","year":"2018","journal-title":"EJNMMI Phys"},{"key":"R102-20260528","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.mric.2016.12.001","article-title":"Attenuation correction of PET\/MR imaging","volume":"25","author":"Chen","year":"2017","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"R103-20260528","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4103\/jcrt.jcrt_1582_23","article-title":"Is intravoxel incoherent motion magnetic resonance imaging useful for predicting hepatocellular cancer recurrence and invasion of the peritumoral zone after transarterial chemoembolization?","volume":"20","author":"Zhao","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R104-20260528","author":"Hall","year":"2012","journal-title":"Radiobiology for the Radiologist: Wolters Kluwer Health"},{"key":"R105-20260528","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect","volume":"39","author":"Rodr\u00edguez-Ruiz","year":"2018","journal-title":"Trends Immunol"},{"key":"R106-20260528","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/cr.2017.155","article-title":"Mitochondrial metabolism and cancer","volume":"28","author":"Porporato","year":"2018","journal-title":"Cell Res"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_707_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:36:50Z","timestamp":1787845010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_707_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_707_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-04-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}